|Other Names||Ubiquitin-like protein FUBI, FAU|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1600a was selected from the N-term region of human FUBI. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FUBI is the cellular homolog of the fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV). It is a fusion protein consisting of the ubiquitin-like protein fubi at the N terminus and ribosomal protein S30 at the C terminus. It has been proposed that the fusion protein is post-translationally processed to generate free fubi and free ribosomal protein S30. Fubi is a member of the ubiquitin family, and ribosomal protein S30 belongs to the S30E family of ribosomal proteins. Whereas the function of fubi is currently unknown, ribosomal protein S30 is a component of the 40S subunit of the cytoplasmic ribosome.
Rossman, T.G., et al., Oncogene 22(12):1817-1821 (2003).Kenmochi, N., et al., Genome Res. 8(5):509-523 (1998).Vladimirov, S.N., et al., Eur. J. Biochem. 239(1):144-149 (1996).Kas, K., et al., Genomics 17(2):387-392 (1993).Michiels, L., et al., Oncogene 8(9):2537-2546 (1993).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.